Article
Oncology
Guang-Yi Sun, Hao Jing, Shu-Lian Wang, Yong-Wen Song, Jing Jin, Hui Fang, Yue-Ping Liu, Hua Ren, Yu Tang, Xu-Ran Zhao, Yu-Chun Song, Si-Ye Chen, Zhuan-Bo Yang, Bo Chen, Yuan Tang, Ning Li, Ning-Ning Lu, Shu-Nan Qi, Yong Yang, Ye-Xiong Li
Summary: This study compared the efficacy of trastuzumab in HER2-positive breast cancer patients with that of HER2-negative patients, showing that trastuzumab can reduce locoregional recurrence and improve disease-free survival. Trastuzumab treatment in HER2-positive breast cancer patients provides comparable outcomes to those in HER2-negative patients.
FRONTIERS IN ONCOLOGY
(2021)
Editorial Material
Oncology
Alicia F. C. Okines, Nicholas C. Turner
Summary: HER2 amplification heterogeneity is linked to resistance to trastuzumab emtansine in the neoadjuvant setting, highlighting the significance of determining whether varying HER2-positive cancer types require distinct treatment approaches.
Review
Oncology
G. Nader-Marta, D. Martins-Branco, E. de Azambuja
Summary: HER2-positive breast cancer is a subtype of breast malignancy with aggressive behavior and high recurrence rates. The combination of trastuzumab, pertuzumab, and a taxane remains the preferred first-line therapy. Recent studies have shown that trastuzumab deruxtecan is more effective than trastuzumab emtansine as a second-line treatment. Other treatment options include T-DM1, tucatinib, trastuzumab, and capecitabine, as well as trastuzumab with different chemotherapy partners.
Article
Oncology
Hanne Vos, Kathleen Lambein, Francois Richard, Bram Marien, Ines Nevelsteen, Kevin Punie, Hans Wildiers, Lieze Berben, Annouschka Laenen, Giuseppe Floris, Christine Desmedt, Ann Smeets
Summary: The study compared the tumor immune microenvironment between TNBC and hormone receptor-negative HER2-positive breast cancer, showing comparable results that may have implications for the use of immune checkpoint inhibition in patients with hormone receptor-negative HER2-positive breast tumors.
Article
Oncology
Elli-Noora Hannikainen, Johanna Mattson, Peeter Karihtala
Summary: Retrospective data analysis of 119 patients with HER2-positive breast cancer treated with neoadjuvant systemic treatment showed that achieving a pathological complete response (pCR) was associated with better prognosis, while moderate immunohistochemical HER2 expression was associated with worse prognosis.
Article
Oncology
Natsuki Teruya, Hiroaki Inoue, Rie Horii, Futoshi Akiyama, Takayuki Ueno, Shinji Ohno, Shunji Takahashi
Summary: The study investigated the predictive and prognostic value of intratumoral heterogeneity and conventional clinicopathological factors in ER+HER2+ breast cancer. The results showed that the composition of tumor cells was associated with prognosis, and the combination of posttreatment Ki67 and complete pathological response could more accurately predict prognosis.
Article
Biochemistry & Molecular Biology
Fei Xing, Hongli Gao, Guanglei Chen, Lisha Sun, Jiayi Sun, Xinbo Qiao, Jinqi Xue, Caigang Liu
Summary: This study uncovered the role of CMTM6 in trastuzumab-resistant HER2+ breast cancer. High expression of CMTM6 was associated with worse survival and affected the stability of HER2 protein. These findings suggest CMTM6 as a potential prognostic marker and therapeutic target for overcoming trastuzumab resistance.
Article
Oncology
Nanae Horisawa, Yayoi Adachi, Daiki Takatsuka, Kazuki Nozawa, Yuka Endo, Yuri Ozaki, Kayoko Sugino, Ayumi Kataoka, Haruru Kotani, Akiyo Yoshimura, Masaya Hattori, Masataka Sawaki, Hiroji Iwata
Summary: The study retrospectively reviewed data from nearly 5000 primary breast cancer patients to determine the frequency of HER2-low and compare the prognosis of HER2-low patients with HER2-negative patients. The research found that HER2-low patients did not have significantly different prognosis than HER2-0 patients. Tailoring therapies for HER2-low early breast cancer patients based on hormone receptor status may be considered.
Article
Oncology
Maria del Mar Noblejas-Lopez, Cristina Nieto-Jimenez, Eva M. Galan-Moya, David Tebar-Garcia, Juan Carlos Montero, Atanasio Pandiella, Miguel Burgos, Alberto Ocana
Summary: The study demonstrated that the PROTAC compound MZ1 based on BET inhibitors can effectively inhibit the proliferation of HER2+ breast cancer cells, and when combined with trastuzumab, it significantly decreases cell proliferation, formation of three-dimensional structures, and invasiveness, promotes cell apoptosis, and alters apoptosis-related biochemical processes. In vivo studies also showed that the combination treatment of MZ1 and trastuzumab reduced tumor volume in xenografted mice, suggesting a potential novel therapeutic strategy for HER2+ breast cancer.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Susanna Nguy, S. Peter Wu, Cheongeun Oh, Naamit K. Gerber
Summary: The study found that adding HER2 therapy to endocrine therapy did not significantly improve overall survival in non-metastatic ER+/HER2+ breast cancer patients who did not receive chemotherapy.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Sibylle Loibl, Chiun-Sheng Huang, Max S. Mano, Eleftherios P. Mamounas, Charles E. Geyer, Michael Untch, Jean-Christophe Thery, Ingo Schwaner, Steven Limentani, Niklas Loman, Kristina Lubbe, Jenny C. Chang, Thomas Hatschek, David Tesarowski, Chunyan Song, Sanne Lysbet de Haas, Thomas Boulet, Chiara Lambertini, Norman Wolmark
Summary: In HER2-negative breast cancer patients, T-DM1 treatment may be more effective than trastuzumab.
Article
Oncology
Kang Wang, Lun Li, Sebastia Franch-Exposito, Xin Le, Jun Tang, Qing Li, Qianxue Wu, Laia Bassaganyas, Jordi Camps, Xiang Zhang, Hongyuan Li, Theodoros Foukakis, Tingxiu Xiang, Jiong Wu, Guosheng Ren
Summary: High-grade ER(+)HER2(-) breast cancer shows distinct clinical and molecular characteristics compared to low-grade tumors, with a worse prognosis, suggesting the need for clinical trials to test novel therapies.
MOLECULAR ONCOLOGY
(2022)
Review
Oncology
Daniele Galanti, Alessandro Inno, Maria La Vecchia, Nicolo Borsellino, Lorena Incorvaia, Antonio Russo, Stefania Gori
Summary: Brain metastases are often associated with HER2+ breast cancer, and systemic therapy with trastuzumab has been the mainstay. Other HER2-targeted agents have been introduced in clinical practice, with newer agents such as neratinib, tucatinib, and trastuzumab deruxtecan showing interesting activity against brain metastases. Further research is needed to elucidate the optimal sequence of these agents and their combination with local treatment.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Oncology
Melanie Royce, Christy L. Osgood, Anup K. Amatya, Mallorie H. Fiero, C. J. George Chang, Tiffany K. Ricks, Krithika A. Shetty, Jeffrey Kraft, Junshan Qiu, Pengfei Song, Rosane Charlab, Jingyu Yu, Kathryn E. King, Anshu Rastogi, Brian Janelsins, Wendy C. Weinberg, Kathleen Clouse, Vicky Borders-Hemphill, Lindsey Brown, Candace Gomez-Broughton, Zhong Li, Thuy Thanh Nguyen, Zhihao Qiu, Anh-Thy Ly, Suyoung Chang, Tingting Gao, Chi-Ming Tu, Bellinda King-Kallimanis, William F. Pierce, Kelly Chiang, Clara Lee, Kirsten B. Goldberg, John K. Leighton, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
Summary: Margetuximab-cmkb in combination with chemotherapy was granted regular FDA approval for the treatment of HER2-positive metastatic breast cancer patients who have received two or more prior anti-HER2 regimens. The SOPHIA study demonstrated that margetuximab had a longer median progression-free survival compared to trastuzumab when both were combined with chemotherapy. Infusion-related reactions were reported as important safety signals associated with margetuximab plus chemotherapy.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Yoshiya Horimoto, Yumiko Ishizuka, Yuko Ueki, Toru Higuchi, Atsushi Arakawa, Mitsue Saito
Summary: For HER2-positive tumors, there was no difference in disease-free survival between IHC(2+)/FISH(+) tumors and IHC(3+) tumors, but there was a difference in survival after developing metastasis.
Article
Oncology
Amy Kwan, Natalie Winder, Emer Atkinson, Haider Al-Janabi, Richard J. Allen, Russell Hughes, Mohammed Moamin, Rikah Louie, Dhanajay Evans, Matthew Hutchinson, Drew Capper, Katie Cox, Joshua Handley, Adam Wilshaw, Taewoo Kim, Simon J. Tazzyman, Sanjay Srivastava, Penelope Ottewell, Jayakumar Vadakekolathu, Graham Pockley, Claire E. Lewis, Janet E. Brown, Sarah J. Danson, Joe Conner, Munitta Muthana
Summary: This study demonstrates that oncolytic virus HSV1716 can activate the antitumor functions of immune cells and reprogram tumor-associated macrophages to a less immunosuppressive phenotype. HSV1716 administration led to marked tumor shrinkage in primary mammary tumors and a decrease in metastases, associated with increased recruitment/activation of cytotoxic T cells and a reduction in regulatory T cells.
MOLECULAR CANCER THERAPEUTICS
(2021)
Review
Immunology
Stefania Cuzzubbo, Sara Mangsbo, Divya Nagarajan, Kinana Habra, Alan Graham Pockley, Stephanie E. B. McArdle
Summary: The discovery of tumor antigens has led to the development of cancer vaccines, but many antigens lack immunogenicity. Adjuvants are added to vaccine formulations to trigger immune responses. Aging can lead to immunosenescence and chronic inflammation.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Erin G. Shackleton, Haleema Yoosuf Ali, Masood Khan, Graham A. Pockley, Stephanie E. McArdle
Summary: Prostate cancer is mainly treated with androgen deprivation therapy, but the long-term effectiveness is limited. Immunotherapy has shown poor efficacy in prostate cancer due to the immunosuppressive tumor microenvironment influenced by regulatory T cells, myeloid-derived suppressor cells, and type 2 macrophages.
Article
Cell Biology
Divya Nagarajan, Joshua Pearson, Victoria Brentville, Rachael Metheringham, A. Graham Pockley, Lindy Durrant, Stephanie E. McArdle
Summary: Managing patients with triple-negative breast cancer (TNBC) remains a clinical challenge, but the ImmunoBody-HAGE vaccine can generate specific T-cell responses and recognize TNBC cells as well as other cancer cells.
IMMUNOLOGY AND CELL BIOLOGY
(2021)
Review
Pathology
C. van Dooijeweert, P. J. van Diest, I. O. Ellis
Summary: Histologic grading is a simple and cost-effective method to assess tumor behavior in invasive breast cancer, with important prognostic value. Properly performed histologic grading is crucial for guiding treatment decisions in breast cancer patients.
Article
Biochemistry & Molecular Biology
Peter Aldiss, Jo E. Lewis, Irene Lupini, Ian Bloor, Ramyar Chavoshinejad, David J. Boocock, Amanda K. Miles, Francis J. P. Ebling, Helen Budge, Michael E. Symonds
Summary: This study demonstrates that chronic suppression of adaptive thermogenesis leads to weight gain and increased fat mass in rodents. Living in a cool environment (20 degrees C) and treatment with a β3-adrenoreceptor agonist (YM-178) had minimal effects on metabolic health in obese rats raised at thermoneutrality.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Chemistry, Multidisciplinary
Faith H. N. Howard, Haider Al-Janabi, Priya Patel, Katie Cox, Emily Smith, Jayakumar Vadakekolathu, A. Graham Pockley, Joe Conner, James F. Nohl, Dan A. Allwood, Cristal Collado-Rojas, Aneurin Kennerley, Sarah Staniland, Munitta Muthana
Summary: The coassembly of magnetic nanoparticles and herpes simplex virus enhances tumor targeting, protects the virus, promotes immune response, and leads to tumor shrinkage and increased survival.
Article
Genetics & Heredity
Esther Danenberg, Helen Bardwell, Vito R. T. Zanotelli, Elena Provenzano, Suet-Feung Chin, Oscar M. Rueda, Andrew Green, Emad Rakha, Samuel Aparicio, Ian O. Ellis, Bernd Bodenmiller, Carlos Caldas, H. Raza Ali
Summary: Imaging mass cytometry profiling of 693 breast tumors revealed 10 recurrent tumor microenvironment spatial structures, associated with genomic profiles and outcomes. These multicellular structures within the TME, varying in vascular content, stromal activation, and leukocyte composition, could improve patient stratification and link spatial organization to local TME function.
Article
Cell Biology
Islam M. Miligy, Michael S. Toss, Kylie L. Gorringe, Ian O. Ellis, Andrew R. Green, Emad A. Rakha
Summary: High AURKA expression is associated with aggressiveness features in DCIS and may be a predictive marker for DCIS progression to invasive disease.
Article
Oncology
Pauline Le Vu, Jayakumar Vadakekolathu, Sarra Idri, Holly Nicholls, Manon Cavaignac, Stephen Reeder, Masood A. Khan, Dennis Christensen, Alan Graham Pockley, Stephanie E. McArdle
Summary: The study found that peripheral blood of prostate cancer patients exhibits immune responsiveness to the MutPAP42mer peptide, and immunization of mice produces T cell-driven immunity against wild-type PAP, suggesting the potential for generating protective anti-tumor immunity in prostate cancer patients.
Review
Cell Biology
Ian O. Ellis, Emad A. Rakha, Gary M. Tse, Puay Hoon Tan
Summary: The International Collaboration on Cancer Reporting (ICCR) has developed an international dataset for breast cancer pathology reporting, aiming to provide a unified approach worldwide. The dataset includes essential and optional data items based on a critical review and discussion of current evidence. The process concludes with international public consultation and publication on the ICCR website to promote high-quality, standardised pathology reporting globally.
Article
Oncology
Sophie Seier, Ali Bashiri Dezfouli, Philipp Lennartz, Alan Graham Pockley, Henriette Klein, Gabriele Multhoff
Summary: This study shows that elevated levels of circulating Hsp70 could be used as a tumor biomarker in NSCLC patients with advanced UICC stages. The levels of Hsp70 were significantly higher in advanced tumor stages compared to healthy controls and early-stage tumor patients, and the levels increased progressively with higher UICC tumor stages. Additionally, the proportions of CD4+ T helper cells were decreased, while the proportions of CD8+ cytotoxic T cells and CD94+ NK cells were increased. These findings suggest that measuring circulating Hsp70 levels may help predict advanced tumor stages in NSCLC.
Review
Oncology
Peter Vaupel, Helmut Piazena, Markus Notter, Andreas R. Thomsen, Anca-L. Grosu, Felix Scholkmann, Alan Graham Pockley, Gabriele Multhoff
Summary: Mild hyperthermia (mHT) has significant effects on tumor oxygenation, which enhances the efficacy of radiotherapy, chemotherapy, and immunotherapy. The underlying mechanisms and the extent of these effects are not fully understood. This review discusses the biological mechanisms induced by mHT that are relevant to radio-oncology and immunotherapy.
Article
Biochemistry & Molecular Biology
Alexia Xanthopoulos, Ann-Kathrin Samt, Christiane Guder, Nicholas Taylor, Erika Roberts, Hannah Herf, Verena Messner, Anskar Trill, Katharina Larissa Kreszentia Holzmann, Marion Kiechle, Vanadin Seifert-Klauss, Sebastian Zschaeck, Imke Schatka, Robert Tauber, Robert Schmidt, Katrin Enste, Alan Graham Pockley, Dominik Lobinger, Gabriele Multhoff
Summary: Hsp70 is overexpressed in many tumors and selectively presented on the plasma membrane of tumor cells. It can be considered a universal tumor biomarker. Circulating levels of Hsp70 can serve as a predictive biomarker for therapeutic failure in early-stage tumors and as a target for the isolation of circulating tumor cells in different tumor diseases.
Article
Sport Sciences
Karah J. Dring, Simon B. Cooper, Ryan A. Williams, John G. Morris, Caroline Sunderland, Gemma A. Foulds, A. Graham Pockley, Mary E. Nevill
Summary: Adiposity and physical fitness are important determinants of metabolic health in adolescents. Greater adiposity is associated with a poorer inflammatory profile, while better physical fitness is associated with better metabolic health. Future research should focus on interventions to reduce adiposity and improve physical fitness in order to promote lifelong health.
FRONTIERS IN SPORTS AND ACTIVE LIVING
(2022)
